Biopharmaceutical Fellowships Pioneering new possibilites for the rare disease community
The fellowship team is extremely dynamic and collaborative. We’re all looking forward to making a difference for rare disease patients.” —First-year fellows
About Alexion Serving patients in
75
countries
30+
years of leadership in rare disease
...................................................................................................................
7
rare diseases globally
6
globally approved medicines
About Alexion, AstraZeneca Rare Disease. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Fellowship Program Overview.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Global Medical Communications–Global Medical Affairs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Global Patient Safety. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Global Regulatory Affairs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Global Value, Access & Pricing.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Product Development and Clinical Supply. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 US Market Access.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 US Medical Affairs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 US Medical Affairs: Promotional Review & Marketing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
Massachusetts College of Pharmacy and Health Sciences (MCPHS).. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30 Application Requirements. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
Our mission is to transform the lives of people affected by rare diseases through the development and delivery of innovative medicines, as well as supportive technologies. At Alexion, AstraZeneca Rare Disease we invest in and value people who believe in the importance of our mission and understand what it takes to deliver on it. Our culture is rooted in integrity, inclusiveness and our dedication
great unmet need and opportunity to help patients and families fully live their best lives. Our development efforts focus on the core therapeutic areas of hematology, nephrology, rare cancers, neurology, endocrinology, bone metabolism and cardiology. We continue to lead in complement science by exploring new targets, and expand beyond complement to strengthen our clinicalstage pipeline through internal and external
to joining and supporting the communities in
development opportunities in our core areas.
which we live and work.
Every day, people living with rare diseases,
Today, our internal research efforts focus on
their caregivers and families face fears of the
leveraging our 30+ years of leadership in rare
unknown with courage, tenacity and grace.
disease. This knowledge allows us to innovate
We believe it is our responsibility to listen to,
and evolve into new areas where there is
understand and change their lives.
About Alexion, AstraZeneca Rare Disease
During the fellowship, we’ve had multiple opportunities to collaborate on several cross-functional projects and champion new solutions for our patients.” —Second-year fellows
4
Our values Our cultural values are the guiding principles behind why and how we do our important work. The work we do is guided by people affected by rare diseases. We are driven to continuously innovate and create meaningful value in all we do to help patients and families fully live their best lives.
We follow the science
We put patients fIrst
We play to win
Alexion, AstraZeneca Rare Disease is headquartered in Boston, Massachusetts. Each fellowship program is two years in duration and most will be based in Boston.
We do the right thing
We are entrepreneurial
Our Commitment to Inclusion & Diversity We create a working environment that fosters continuous innovation, constant learning and propels our growth as individuals and for our company. That is why we aim to create an inclusive workplace and a workforce that reflects our communities and the patients we serve.
6
This includes equitable compensation, benefits and opportunities for development and advancement. We believe that inclusion is a right and diversity is a strength. Both make a fundamental contribution to the success of our company because innovation requires breakthrough ideas that only come from a diverse workforce empowered to challenge conventional thinking.
We believe our shared creativity unlocks challenges and brings new solutions. Incorporating Inclusion and Diversity (I&D) across all aspects of our organization is imperative to innovating for patients, continuous learning and growing as individuals and as a company. Inclusion and diversity is one of the foundations of our People strategy — driving innovation, engagement and a sense of connection and belonging.
We focus on four areas: Empowering inclusive leadership Fostering an environment where we each speak our minds Building and sustaining a diverse leadership and talent pipeline Contributing to society, which includes our commitments to supplier diversity, clinical trial diversity and health equity
Disease Areas Rare Neurology Rare Cardiology & Amyloidosis Rare Bone & Endocrine Disorders
Rare Hematology, Nephrology & Transplant Rare Tumors
Alexion/MCPHS Fellowship Program Alexion, in collaboration with Massachusetts College of Pharmacy and Health Sciences (MCPHS), is pleased to offer exceptional postdoctoral fellowship programs to candidates obtaining a Doctor of Pharmacy.
One of the most rewarding aspects of my position is serving as a preceptor and mentor to fellows. Seeing talented professionals grow through this accelerated leadership program and then make meaningful contributions across the company is incredibly fulfilling.” —Krystal Huey, PharmD, MS
8
Through this experience, fellows will gain exposure to the biopharmaceutical industry, enhancing their understanding and establishing a foundation as an industry professional.
Programs Global Medical Communications– Global Medical Affairs 2 positions. Boston, MA Global Patient Safety 1 position. Boston, MA Global Regulatory Affairs 1 position. Boston, MA Global Value, Access & Pricing Not Recruiting Product Development & Clinical Supply 1 Position. New Haven, CT US Market Access Not Recruiting US Medical Affairs 1 Position. Boston, MA US Medical Affairs: Promotional Review & Marketing 1 Position. Boston, MA
Global Medical Communications– Global Medical Affairs 2-Year Program Medical Information 9 months
Medical Review 9 months
Elective 6 months
The Global Medical Affairs team plays a critical role in raising awareness of rare diseases and ensuring healthcare providers and patients have access to accurate and meaningful medical information.
before completing a customizable elective, building expertise across the full spectrum of medical communications in a fast-paced, patient-centric environment.
This fellowship offers immersive experience across both Global Medical Communications and Global Medical Review — two functions that sit at the heart of how Alexion communicates its science to the world. Fellows rotate through Medical Information and Medical Review
Focused Development
The fellowship’s unique rotational structure encourages innovation and cross-functional collaboration, allowing me to grow professionally and develop new skills while contributing meaningfully to patient care.” — Samantha Gorski, PharmD
10
• Communication and Interpersonal Skills
• Collaborating for Solutions
• Medical and Scientific Expertise
• Project Management and Prioritization
• Strategic Thinking
• Driving for Results
Dear Prospective Fellow, Thank you for your interest in the Alexion Fellowship Program in collaboration with Massachusetts College of Pharmacy and Health Sciences (MCPHS) University. As we pursue our mission of transforming lives through the development of innovative therapies for patients with rare diseases in neurology, hematology, and other therapeutic areas—the Global Medical Affairs team, including Global Medical Communications, continues to play a critical role in serving these patients and raising awareness of the challenges of living with a rare disease. I wish you the best of luck as you explore the available opportunities and encourage you to consider the Alexion Fellowship Programs. Sincerely, Christophe Hotermans, MD, PhD Senior Vice President, Head of Global Medical Affairs, Alexion, AstraZeneca Rare Disease
The Team Diane Lawson, PharmD, RPh Program Director & Program Lead Diane is the Senior Director and Head of the Neurology Medical Information-Medical Review team, partnering with US and Global functions. Her 20-year pharmaceutical experience has consisted of various leadership positions managing medical publications, medical information, and R&D programs designed to advance biopharmaceutical careers for physicians and pharmacists new to industry. Prior to joining Alexion in 2018, Diane received her Bachelor of Science in Pharmacy at the University of Iowa, and her Doctor of Pharmacy from the University of Florida. Ahsan Jamil, PharmD Preceptor Ahsan is the Senior Director and Head of Hematology, Nephrology, Transplant within the Global Medical Information-Medical Review team. He has experience across various medical affairs roles and companies within the pharmaceutical industry. Prior to joining Alexion, his experience spanned several therapeutic areas including oncology, hematology, cardiovascular, metabolics, biosimilars and general medicines. Ahsan received his Doctor of Pharmacy from Rutgers University.
Rotation 1 Objectives
Rotation 2 Objectives
Global Medical Information
Global Medical Review
•
Develop and deliver high-quality, balanced and timely written or verbal medical and scientific information in response to requests from health care professionals and consumers
•
Contribute to the development and maintenance of medical information written responses to address a vast array of inquiries to aid HCPs in clinical decision-making
•
Support Medical Information booth activities prior to, during and after professional scientific meetings and medical congresses
•
Partner with cross-functional teams (e.g., Medical Affairs, Marketing, Clinical Development, Competitive Intelligence, Pharmacovigilance, Biostatistics, Medical Training, Corporate Communications) to contribute to product launch activities, development of competitive readiness resources and deliverables that align with medical strategic initiatives
12
•
Develop strategic partnerships with stakeholders from Medical Affairs, Clinical Development, Regulatory Affairs, Legal, Marketing, Compliance and others to support the development and approval of robust, compelling and accurate materials for healthcare providers, patients and other groups
•
Provide comprehensive medical review and consultative expertise for product launch campaigns, congress symposia, speaker decks and other materials used by field Medical Affairs and Commercial colleagues
•
Collaborate with subject matter experts across Medical Affairs and Clinical Development to ensure the content of promotional and medical materials is scientifically appropriate, clinically relevant and aligned to company strategy
•
Participate in live meetings of Promotional and Medical Review Committees, which are composed of a collaborative, cross-functional team, including Medical, Legal and Regulatory review colleagues and Commercial or Medical content creators
On the GMC-GMA team, I’ve found a learning environment that encourages curiosity and makes each new experience feel meaningful, practical and tied to Alexion’s commitment to rare disease.” —Jeremy Mocklin, PharmD
Elective Rotations Possible
• Medical Science Liaison • Scientific Communications • Regulatory Affairs • Clinical Development
• Health Economics and Outcomes Research • Global Patient Safety • Marketing
Current Fellows Marwa El-Mouwfi, PharmD Second-year Fellow
Jeremy Mocklin, PharmD First-year Fellow
“Through mentorship and collaboration, this fellowship has shaped my career— deepening my medical communications expertise while advancing a mission that transforms rare disease patients’ lives.”
“Just weeks into my fellowship, I’ve already had the opportunity to contribute to medical information resources that answer important questions and support consistent scientific communication across teams.”
Samantha Gorski, PharmD Second-year Fellow
Zein Dib, PharmD First-year Fellow
“At Alexion, collaboration and innovation are at the forefront. This forward-thinking enviroment ensures I can leverage and grow my clinical skills.”
“Alexion has given me the opportunity to build meaningful connections, broaden my knowledge, and contribute to work that brings hope to patients and families living with rare diseases worldwide.”
Hugo Mari, PharmD, MBA First-year Fellow “As a member of the GMC-GMA team, I’m grateful to learn from exceptional mentors, collaborate across functions, and contribute to meaningful work that challenges me to grow.”
Global Patient Safety 2-Year Program Onboarding ~ 6 weeks
Safety Scientist Rotation 1:
Post-marketing Drug Safety ~5 months
Safety Scientist Rotation 2:
Clinical Development Drug Safety ~5 months
The Global Patient Safety (GPS) team provides continuous, proactive assessment and communication of patient risks associated with Alexion’s therapies — ensuring every product upholds the highest standards of safety throughout its lifecycle. This fellowship equips fellows with the scientific rigor and strategic thinking needed to build a successful career in pharmacovigilance, through core rotations spanning post-marketing and clinical development drug safety. Fellows gain a comprehensive understanding of benefit-risk assessment for orphan drugs treating ultrarare diseases, while collaborating across clinical development, medical affairs, regulatory affairs, and quality. An elective rotation allows fellows to further tailor the experience to their individual career interests.
14
Elective Rotation* ~1-3 months
Return to
Safety Scientist Rotation ~8 months
Focused Objectives Develop the ability to think strategically and understand the role of Patient Safety in the lifecycle of products Understand the benefit/risk balance of orphan drugs designed to treat devastating diseases Cultivate and utilize knowledge in international pharmacovigilance regulations and guidelines, to increase process effectiveness Participate and engage in cross-functional team projects involving Commercial, Marketing, Medical Affairs and Regulatory Affairs to disseminate Global Patient Safety messages Utilize scientific knowledge and research skills to support safety surveillance and risk management decisions Master skills to communicate complex safety messages cross-functionally and influence decision making
Dear Prospective Fellow, Thank you for your interest in the Global Patient Safety Fellowship. Each year, this distinguished program is designed to train the next generation of pharmacovigilance professionals, preparing fellows to make meaningful contributions to the development of innovative rare disease therapies that have the potential to transform lives. In GPS, fellows gain hands-on experience across all of Alexion’s therapeutic areas and throughout the full product lifecycle, collaborating with diverse teams including clinical development, medical affairs, quality, and regulatory affairs. We seek colleagues who are passionate about ensuring every patient’s well-being is upheld throughout the entire drug development process. I encourage you to consider this unique opportunity and look forward to welcoming a fellow who shares our unwavering commitment to patients. Sincerely, Arshad Mujeebuddin, MD Vice President of Patient Safety, Alexion, AstraZeneca Rare Disease
*Dependent upon interest and availability, the fellow may elect to rotate through additional areas within Safety or other functional areas (eg. Regulatory Affairs, Medical Affairs, Global Medical Communications, Epidemiology, HCP and Patient Marketing)
The Team Kate Szymaniak, PharmD, RPh Program Lead Kate is a Director, Safety Scientist with over 12 years of industry experience in Pharmacovigilance overseeing the safety of products throughout their lifecycle. She joined Alexion in 2019 and is currently responsible for the oversight of safety scientist related activities across the rare disease portfolio. Prior to joining Alexion, Kate worked at Sanofi Genzyme where she started her career as a Pharmacovigilance Postdoctoral Fellow and later transitioned to a Pharmacovigilance Scientist role. Kate received her PharmD from Massachusetts College of Pharmacy and Health Sciences. Samirah Qureshi, MD Preceptor Samirah is a pediatrician working as a Global Patient Safety Physician at Alexion, with more than 12 years of experience in pharmacovigilance and drug safety, including over 6 years at Alexion. She provides strategic safety leadership across investigational and marketed products, with expertise in signal detection, risk management, benefit-risk assessment, and global safety surveillance. Her therapeutic experience spans complement-mediated disorders, hematology, nephrology, and neuromuscular diseases. Prior to Alexion, Samirah worked at Biogen. She holds an MD and has broad research experience with Harvard Medical School. Rosetta Tolley, PharmD, RPh Preceptor Rosetta is a Senior Manager, Safety Scientist in Alexion’s Global Patient Safety Team. She began her career at Alexion as a Global Patient Safety Fellow and completed the two-year fellowship program in 2025. She earned her Doctor of Pharmacy from Ohio Northern University and currently works within metabolic, neurology, and gene therapy therapeutic areas.
Current Fellows Shreya Patel, PharmD, RPh Second-year Fellow
The collaborative approach of the team ensures the well-being of patients at every stage on their journey.” —Shreya Patel, PharmD, RPh
“My experience has been incredibly rewarding, fostering professional growth while deepening my understanding of pharmacovigilance and the critical role of patient safety in drug development and post-market support. Heer Patel, PharmD, MPH First-year Fellow “I am excited to learn from the GPS team and contribute to making a meaningful difference in patients’ lives. I look forward to contributing to Alexion’s mission and advancing outcomes for patients living with rare diseases.”
Global Regulatory Affairs 2-Year Program Electives Possible
• Product Strategy
•C hemistry, Manufacturing, and Controls (CMC)
Global Regulatory Affairs (GRA) is responsible for the design and execution of innovative regulatory strategies that drive the advancement and approval of Alexion’s therapies — from early development through commercialization. This fellowship provides fellows with hands-on exposure to a breadth of GRA sub-functions, including product strategy, CMC, regulatory labeling, intelligence, and operations, all while directly contributing to Alexion’s rare disease portfolio. Fellows rotate through designated preceptors and cross-functional teams, building a broad regulatory foundation that can be tailored to individual interests and professional development goals. The ability to work across both US and global health authority interactions makes this program uniquely comprehensive for aspiring regulatory professionals.
• Regulatory Labeling
• Regulatory Intelligence & Policy
• Regulatory Operations
Focused Objectives Year 1 Assist with the planning, development, review, approval and updating of various documents critical to the success of Regulatory initiatives Support the Regulatory leads with their contributions to Regulatory projects and provide helpful insight and guidance Observe how to develop and execute regulatory strategy and work successfully with cross-functional teams and US and global health authorities Gain a solid understanding of the current Regulatory landscape, including relevant guidances, enforcement actions, laws, rules and/or regulations
Year 2 Represent Regulatory as an integral member at crossfunctional meetings by providing regulatory insight, owning action items and contributing feedback and guidance on various documents and projects Lead cross-functional teams through appropriate processes to comply with regulatory driven commitments Support (and potentially drive) the planning, preparation and submission of regulatory initiatives Serve as coordinator for US and global health authority interactions
Helping advance innovative treatments, while also building lasting professional relationships, has made my fellowship an excellent experience.” —Sabrina Zhang, PharmD
16
Dear Prospective Fellow, For more than a decade, the Global Regulatory Affairs Fellowship has recruited talented pharmacists to gain meaningful experience in the regulatory profession — and we are proud to continue that tradition. In GRA, fellows work across the full drug development spectrum, helping translate impactful science into innovative regulatory strategies that bring lifechanging therapies to patients with high unmet medical need. Our team of over 200 people across 18 countries champions diversity and collaboration, creating a rich environment for learning and growth. If you are passionate about life sciences and driven to make a difference for patients with rare diseases, I encourage you to apply — we look forward to being inspired by you. Sincerely, Sarah Rhee, MS Vice President, Head of Alexion Regulatory Affairs
The Team Erica Lee, RAC Preceptor and Program Lead Erica is a Group Director in the Global Regulatory Affairs, Regulatory Science & Execution group at Alexion. In this role, she leads a team responsible for the end-to-end execution of regulatory strategies and leading program teams. She has more than 16 years of pharmaceutical experience in roles related to assay development and regulatory strategy. Prior to joining Alexion, Erica worked at Shire Pharmaceuticals and Syntimmune, Inc., where she led CMC strategy for rare diseases. Erica received her Bachelor of Arts in Biology and Chemistry from Clark University and holds a Regulatory Affairs Certification for Drugs through the Regulatory Affairs Professionals Society. Michelle Taylor, MS Preceptor Michelle is a Senior Manager in the Global Regulatory Affairs, Labeling group at Alexion, where she supports CCDS compliance activities and the Global Labeling Business Process. She brings 8 years of regulatory experience, along with 6 years of clinical research experience. Prior to joining Alexion, Michelle held roles at Shire Pharmaceuticals and Brigham and Women’s Hospital, where she worked with the TIMI Study Group. She earned her bachelor’s degree in Marketing from UMass Boston and her master’s degree in Clinical Research from Emmanuel College.
Current Fellows Eli Carbo Ontiveros, PharmD Second-year Fellow “The GRA Fellowship offers tailored experiences, exceptional mentorship, and hands-on opportunities across diverse areas. Fellows build regulatory expertise, meaningful connections, and contribute to delivering innovative medicines to rare disease patients.” Sabrina Zhang, PharmD First-year Fellow “I’m excited to gain hands-on experience across key regulatory sub-functions and work with U.S. and global health authorities to help people with rare diseases access life-changing therapies.”
Global Value, Access & Pricing 2-Year Program Value Proposition Development
Pricing & Reimbursement Strategy
Alexion’s Global Value, Access & Pricing (GVAP) team shapes the evidence, strategies, and tools that determine how patients around the world gain access to life-changing rare disease therapies. This fellowship places fellows at the intersection of GVAP and Health Economics and Outcomes Research (HEOR), developing expertise in value proposition development, pricing and reimbursement strategy, HTA systems, and evidence generation. Fellows are embedded within core launch and program teams, contributing directly to access strategies across Alexion’s portfolio while gaining exposure to complementary functions including US Market Access and Business Development. The program’s flexibility allows fellows to customize their rotational journey in line with their interests and organizational priorities.
NOT RECRUITING
18
Global Healthcare & HTA Insights
Target Product Profile Creation
Focused Objectives Support development of differentiated target product profile that fulfills cross stakeholder needs aligned to robust value proposition Develop global pricing and reimbursement (P&R) strategies and framework in close collaboration with launch and program teams Create and roll out value and access communication tools and materials to support local P&R submissions and negotiations
Cultivate understanding of global health care, HTA systems and latest developing trends especially within rare disease Build a comprehensive understanding of what evidence payers value across market/payer archetypes Influence trial design, outcomes and endpoint strategy to support payer needs Gain exposure to different methodologies to quantify and fill evidence gaps including burden of disease and unmet need
Current Fellows Sophia Serafimov, PharmD, RPh Second-year Fellow “The GVAP fellowship offers unique crossfunctional exposure and ownership of highimpact global access projects focused on advancing sustainable access to rare disease therapies while developing strategic and leadership skills.” Phuong (Josie) Luong, PharmD First-year Fellow “I was drawn to the GVAP Fellowship by the opportunity to understand how strategic decisions translate innovation into meaningful patient access in rare diseases.”
Meaningful ownership of high-impact projects made the fellowship an obvious choice for me and my career.” —Josie Luong, PharmD
Dear Prospective Fellow, We are thrilled to continue the Global Value, Access & Pricing Fellowship in collaboration with MCPHS, and are committed to mentoring new talent through an accelerated, hands-on development experience. The GVAP team works at the intersection of clinical evidence, health economics, and market strategy — shaping access and reimbursement for therapies that transform the lives of patients with rare diseases. This fellowship offers a unique opportunity to develop the core skillset needed to become a future market access leader. I encourage you to consider joining our highly driven team, and I look forward to welcoming our next fellow. Sincerely, Pierrick Rollet Vice President of Global Value, Access & Pricing, Alexion, AstraZeneca Rare Disease
The Team Jennifer Pocoski, PharmD Program Director Jennifer is currently the Global Value, Access & Pricing Head for the metabolic portfolio. Jennifer has held several positions within access and health economics over the last 19 years. She completed her twoyear fellowship at Bayer Pharmaceuticals in Medical Affairs and Health Economics. She received her PharmD from Northeastern University.
Krystal Huey, PharmD, MS Preceptor Krystal is the amyloidosis franchise lead for the metabolics programs. She completed her two-year fellowship at Celgene/BMS in HEOR and GVAP. She received her PharmD from Northeastern University and her MS in Health Outcomes, Policy and Economics from Rutgers University. Mukesh Sharma, PhD Preceptor Mukesh is the Global Head of Pricing Strategy, Early Pipeline, and Business Development at Alexion. He completed his research fellowship at Harvard Medical School after earning a Ph.D. in Biochemistry from Florida State University. Mukesh has authored 15 scientific publications that have been cited in more than 1,800 articles. Over the past decade, he has held leadership roles across U.S. and Global Market Access as well as life sciences strategy consulting. Simu Thomas, M Pharm, MS, PhD HEOR Sponsor Simu is the VP and Global Head of Global Medical Communications, HEOR and Medical Training at Alexion Pharmaceuticals. He has authored more than 35 manuscripts and 75 congress presentations and coauthored book chapters in the field of Health Economics. Simu holds a PhD in Pharmaceutical Economics from the University of Maryland and MS in Pharmacy Administration from the University of Toledo and Pharmacy degrees from Birla Institute of Technology and Science. Simu also serves as Adjunct Assistant Professor at the University of Maryland and Rutgers, The State University of New Jersey. Craig Wakeford, BA, MA HEOR Mentor Craig is currently the Senior Director of HEOR at Alexion. He holds a BA in Economics from the University of Toronto and a Masters in Economics from the University of Ottawa. He has held multiple positions within HEOR and Access in the past 10 years across multiple therapeutic areas.
Product Development & Clinical Supply 2-Year Program Rotational Opportunities Possible: 24 months
•G lobal Clinical Supply Management •E xternal Manufacturing & Forecasting •R andomization & Trial Supply Management • I njectables & Drug Product Development
• Development Supply & Digital Quality • Chemistry Manufacturing & Controls • Device Development • Trial Master File
The Product Development & Clinical Supply (PDCS) fellowship is designed to equip fellows with core skills and expertise to become effective clinical supply managers through applied, hands-on experience. Throughout the program, fellows will build their clinical supply expertise and contribute to advancing Alexion’s mission and values.
Core Rotation Objectives Global Clinical Supply Management
Injectables & Drug Product Development (IDPD)
Pharmacy Manual (PM) and IMP Queries
Ensure on time delivery of Investigational Medicinal Product (IMP) to support clinical trials and patients by overseeing contract manufacturing, packaging, labeling and international distribution.
Collaborate across functions to research, design and execute scientific studies, facilitating the development, characterization and commercial validation of parenteral/ injectable biologic drug products.
Author, coordinate, and manage the end to end development of pharmacy manuals to support clinical trial conduct by providing clear and appropriate IMP handling instructions for clinical sites.
Collaborate with Clinical Operations, Quality Assurance (QA), CMC, Regulatory Affairs and other cross-functional teams, ensuring proper compliance, efficiency and quality of Alexion clinical trial supplies.
Manage the development of various manufacturing unit operations, including but not limited to, drug substance (DS) freeze/thaw, compounding/mixing, sterile filtration, drug product (DP) filling of vials/syringes, visual inspection and DS/DP transportation.
Support cross functional, global study teams in the creation, management, and revision of pharmacy manuals, ensuring clinical sites receive clear and appropriate IMP handling guidance.
Provide strategic clinical supply planning based on study protocol and clinical development plans to guarantee adequate clinical supply and maximize cost efficiency.
Provide support for clinical and commercial manufacturing sites, including participation in regularly scheduled support meetings, ownership of action items, and on-site support as needed.
Ensure all study team and site queries related to drug storage, preparation, handling, and destruction are comprehensively assessed and resolved in a timely manner.
I experienced a front-row seat to drug development, collaborating across functions, contributing to global clinical programs, and supporting the advancement of innovative therapies for patients with rare diseases.” 20
—Hassan Sleiman, PharmD
Dear Prospective Fellow, Thank you for your interest in the Product Development and Clinical Supply Fellowship at Alexion, AstraZeneca Rare Disease. Our partnership with MCPHS is an exciting opportunity to accelerate growth and allow fellows to learn firsthand by supporting Alexion’s clinical studies. The PDCS program equips fellows with the skills to become effective clinical supply managers through hands-on rotations — from global supply management to injectables development and clinical trial systems. Clinical supply for rare disease presents nuanced, meaningful challenges that pave the way for innovative thinking. By joining Alexion, you will become part of a team and community steeped in patient-centered care and cutting-edge science. I look forward to welcoming our next fellow. Sincerely, Mark Swift, JD, BS Executive Director & Head, Clinical Supply and External Manufacturing, Alexion, AstraZeneca Rare Disease
The Team Jennifer Mahon, PharmD, MBA, MS, BS Program Lead Jenn is a Director in Global Clinical Supply & External Manufacturing, in addition to being the Pharmacy Manual Team Lead and PDCS Fellowship Director. Jenn has 20 years of experience within R&D and clinical trials, working at Pfizer, Cardinal Health, BMS and Thermo Fisher before joining Alexion. While at Alexion, Jenn was the Clinical Supply Inspection Lead for Voydeya’s approval in USA, EU and Japan. Crystal Ma, PharmD Global Clinical Supply Management Lead Preceptor Crystal is an Associate Director in Global Clinical Supply Management at Alexion. Currently, she is the lead clinical supply manager for multiple programs in both early and late phase development. With over 8 years of industry experience, she has developed and managed an end-to-end clinical supply chain across various modalities from biologics, small molecules, to CGx. In addition, she also participates in process-improvement workstreams to streamline business workflows within clinical supply management. Crystal received her PharmD from Purdue University and joined Alexion in 2021 after completing a twoyear fellowship in Global Clinical Supply with Pfizer/MCPHS. Katiria Flores, PhD, MS, BS Injectables & Drug Product Development Preceptor Katiria is a Senior Scientist in the Injectables & Drug Product Development group with 8 years of experience specializing in clinical in-use compatibility strategy, pharmacy preparation and administration support, and the development of instructions for use for intravenous and subcutaneous drug products. Her expertise has contributed to more than 15 Alexion therapies and development programs, supporting clinical execution, informing pharmacy guidance, and enhancing drug product usability for both investigational and marketed products. Katiria holds a BS in Industrial Microbiology from the University of Puerto Rico and a PhD in Physiology and Neurobiology from the University of Connecticut.
Current Fellows Hassan Sleiman, PharmD Second-year Fellow “Working in rare and ultra-rare diseases has been especially fulfilling because it enables me to see the meaningful impact our collaborative efforts have on improving the lives of patients with few or no treatment options.” Aleksandar Stajic, PharmD, MBA First-year Fellow “Alexion’s PDCS team stood out to me because it offers the chance to work across multiple teams, strengthen my foundation in product development and clinical supply, and contribute to meaningful innovation in the rare disease space within a highly collaborative environment.”
US Market Access 2-Year Program Elective Rotation 6 months
Access Strategy & Marketing 12 months
Strategic Contracting & Pricing 6 months
The US Market Access (USMA) team leads strategies that ensure patients can access Alexion’s rare disease therapies — balancing the needs of patients, payers, and healthcare systems to deliver treatments that are both clinically impactful and sustainably priced. This fellowship offers fellows the opportunity to contribute directly to payer marketing, contracting and pricing, and access strategy across Alexion’s diverse rare disease portfolio. Core rotations in Access Strategy and Marketing and Strategic Contracting and Pricing are complemented by an elective within the broader US commercial organization, providing exposure to the full landscape of market access in rare disease. Fellows are fully embedded in project teams from day one, solving real-world access challenges that have direct implications for patients.
Core Rotation Objectives Access Strategy and Marketing Assist with the development of a payer value proposition that effectively communicates clinical and economic benefits to support access strategy. Collaborate with HEOR, the Payer Account team, Brand Marketing and Medical Affairs to align on actionable pricing, channel, and payer strategies. Support tactical planning for a key therapeutic area, integrating payer and provider initiatives to optimize access. Partner with Field Reimbursement Managers to ideate, develop and deploy access and reimbursement materials.
Strategic Contracting and Pricing Gain experience in building and delivering value-based drug pricing recommendations for both medical and pharmacy benefit products. Support in driving the estimation of potential return on investment for prospective contracts. Gain experience in modeling contract scenarios pre-deal to inform contracting decisions and forecasts. Coordinate with the Payer Account team to gather inputs and customer intelligence for contract modeling.
Elective Rotations Possible • US Trade/Distribution and Channel Strategy • Strategic Initiatives and Operations • Contract Management •P ayer Customer
• Marketing • Brand Marketing •G lobal Value, Access, and Pricing •E xtension of core rotations
The focus on helping patients and families access the rare disease therapies they need really drives the team to excellence.
NOT RECRUITING
22
—Shawn Carroll, PharmD
Dear Prospective Fellow, Thank you for your interest in the US Market Access Fellowship. Through core rotations in Access Strategy and Payer Marketing, Strategic Contracting and Pricing, and elective opportunities across the US commercial organization, fellows are fully embedded in project teams and positioned at the forefront of market accessin rare disease. Our teams’ purpose is powerful; we only exist to better the lives of patients and their families. We work to ensure that patients have access to our medicines whether insured, underinsured, or uninsured, as innovations only matter if they are accessible to patients. I look forward to welcoming a fellow who shares that commitment. Sincerely, Edward Feeley Vice President, US Market Access, Alexion, AstraZeneca Rare Disease
The Team Subrat Roychoudhary, MS, MBA Head of US Access Strategy and Marketing, Program Lead Subrat leads the US Access Strategy and Marketing team at Alexion. He has more than 15 years of experience in US Market Access. Subrat has MS in engineering from University of Connecticut and an MBA from Cornell University. Beth Goulet, BA, MBA Senior Director, US Access Strategy and Marketing Beth is the US Access Strategy Lead for the Metabolics business unit at Alexion. She has more than 20 years of experience in the industry. Beth earned her BA in philosophy from Harvard University and an MBA from the Wharton School at the University of Pennsylvania. Ben Carroll, PharmD Senior Director, US Access Strategy and Marketing Ben leads US Access Strategy for the Neurology business unit. He has over 15 years of experience in HEOR, Global and US Market Access. Ben earned his PharmD from the University of Rhode Island. Alexandra Burger, PharmD, MPH Associate Director, US Payer Customer Marketing Alexandra leads the Payer Customer Marketing program for the US Market Access team. She completed her own twoyear fellowship at Alexion/AZ and holds a PharmD from Northeastern University and an MPH from MCPHS.
Current Fellow Shawn Carroll, PharmD First-year Fellow “What set the USMA Fellowship apart was the opportunity to work at the intersection of rare disease, launch strategy, and patient access. I am excited to learn from experienced leaders and contribute to strategies that support meaningful outcomes for patients.”
US Medical Affairs 2-Year Program US Medical Excellence 9 Months
US Medical Director / US Medical Science Liaison 9 Months
US Medical Affairs (USMA) is the bridge between Alexion’s science and the healthcare providers and patients it serves — a function that demands deep scientific expertise, strategic thinking, and a passion for rare disease. Through two nine-month rotations and one six-month rotation across US Medical Excellence, an integrated US Medical Director/US Medical Science Liaison rotation, and an elective rotation, fellows gain a holistic view of Medical Affairs through diverse, cross-functional perspectives. The individualized rotation schedule is aligned to major Alexion milestones, ensuring fellows are engaged in work that is strategically meaningful and clinically relevant. The final elective rotation allows fellows to deepen their expertise or explore adjacent areas of the business.
Elective Rotations Possible • US Medical and/or Regulatory Review • Global Medical Information/Scientific Communications • Health Economics and Outcomes Research
• Marketing • Market Access • Global Patient Safety (Pharmacovigilance) • Extension of existing core rotations
Elective 6 Months
Core Rotation Objectives US Medical Excellence Under the guidance of the Medical Communications Leads (MCL)
Develop and update scientific and strategically aligned field materials while building a strong understanding of the medical review process Participate in the planning and execution of USMA activities at national medical congresses Identify, design and deliver trainings to increase scientific knowledge and skill development Contribute to special projects as needed to advance strategic imperatives and enhance USMA capabilities
US Medical Director Build leadership skills and fundamental knowledge in cross-functional strategic planning Lead, with the support of Medical Directors, tactical implementation of key program initiatives Contribute to strategic activities including advisory boards, evidence generation, publication planning and competitive differentiation
US Medical Science Liaison (MSL) Achieve MSL field-readiness certification through completion of the MSL onboarding program Support medical activities at medical congresses through abstract coverage, booth staffing and Key Opinion Leader (KOL) engagement Collaborate with MSLs in their field engagements, learning to capture and report field insights that ultimately influence medical strategy Observe and apply insights to optimize territory plans and stakeholder mapping
The rotations available provide a truly comprehensive view of medical affairs.” —Bria Johnson, PharmD, RPh
24
Dear Prospective Fellow, We are excited to recruit and mentor new talent within the US Medical Affairs team, and this fellowship reflects our commitment to advancing medical expertise and fostering the next generation of rare disease leaders. Through rotations in US Medical Excellence, Medical Director, and Medical Science Liaison roles — plus a customizable elective — fellows gain a comprehensive, well-rounded view of medical affairs within a field that demands constant innovation on behalf of patients with ultra-rare diseases. We are looking for passionate individuals who embody the innovative spirit to break barriers for our patients. I hope you will consider joining us. Sincerely, Naeem Khan Vice President, US Medical Affairs, Alexion, AstraZeneca Rare Disease
The Team Susan Lenhart-Herman, PharmD, RPh, BCPS Program Co-Lead Susan has worked in the pharmaceutical industry for over 20 years gaining a wide range of experiences in field-based medical affairs. In her current role, she is committed to supporting the success of the field-based teams via the development of highly scientific and engaging resources aligned with medical affairs strategy. She has always had a passion for teaching and mentoring and is excited to champion the professional growth and development of the fellows. Rada Zunich, PharmD, RPh Program Co-Lead Rada earned her PharmD in 2023 from the University of North Carolina Eshelman School of Pharmacy. She joined Alexion as the inaugural US Medical Affairs fellow. Following the completion of her fellowship, she transitioned into a full-time position as Senior Manager, Medical Communications Lead for Nephrology.
Current Fellows Sarah Young Second-year Fellow “I appreciate the opportunity to work in ultra-rare diseases because I can truly see the impact our work has on improving patients’ lives.” Owen Juneja Second-year Fellow “The fellowship’s best part? The privilege of mentorship from rare disease leaders who show us the true impact of our work every day.”
Bria Johnson, PharmD, RPh First-year Fellow “’I have appreciated the USMA team’s adaptive and supportive leadership, which has allowed me to tailor my experience and grow as a well-rounded professional.”
US Medical Affairs: Promotional Review & Marketing 2-Year Program US Medical Review 6 Months
US AD Promo 6 Months
The US Medical Affairs: Promotional Review & Marketing Fellowship provides a unique opportunity that bridges three critical functions: US Medical Review, US Regulatory Advertising and Promotional Compliance, and US Marketing. This program offers an unparalleled, cross-disciplinary lens on how scientific rigor, regulatory expertise, and commercial strategy converge to drive breakthroughs in rare diseases, shaping the future of patient care. Tailored for fellows eager to master the lifecycle of promotional and medical materials, from brand planning and strategic development to rigorous regulatory scrutiny and eventual market execution. You’ll collaborate side-by-
US Marketing 6 Months
Elective 6 Months
side with top industry leaders across immersive rotations, sharpening your critical thinking and communication skills to thrive in these high-visibility roles where compliance meets innovative impact. An elective rotation provides additional flexibility to explore adjacent functions aligned with individual career goals.
Elective Rotations Possible • US Medical Science Liaison
• Scientific Communications
• Medical Information
•H ealth Economics and Outcomes Research
• Global Medical Affairs • Clinical Development
•F ield Systems and Analytics
• Global Patient Safety (Pharmacovigilance)
•E xtension of existing core rotations
• US Medical Affairs Pipeline
“ The high quality mentorship makes me confident I have all the tools necessary to build a successful career. —Francielle Mourisso
26
Dear Prospective Fellow,
The Team
The Promotional Review & Marketing Fellowship is dedicated to cultivating emerging talent, offering a comprehensive and immersive experience at the intersection of medical, regulatory, and marketing disciplines.
Matthew Maulis, PharmD Program Lead Matthew is a Director supporting US Medical Review within the Hematology & Nephrology therapeutic area, where he serves as the lead medical reviewer. He earned his PharmD from Lipscomb University in 2018 and subsequently completed a post-doctoral fellowship in Medical Information & Medical Affairs with Sunovion Pharmaceuticals and MCPHS University. Following his fellowship, Matthew remained at Sunovion, serving as both a preceptor and director of their fellowship program.
Designed to be a transformative, hands-on experience, this fellowship explores the dynamic intersection of medical expertise, regulatory compliance, and cutting-edge marketing. Through structured rotations in Advertising and Promotional Compliance, Medical Review, and Marketing— complemented by elective opportunities—fellows will cultivate critical skills while working directly alongside industry experts across key strategic functions within rare disease. We are committed to supporting the professional growth of our next fellow through this exciting and unique opportunity. Sincerely, Matthew Maulis, PharmD Director, US Medical Review Alexion, AstraZeneca Rare Disease
Current Fellows Fayth Morris Second-year Fellow “My first year was extraordinary. I worked on multiple launches and impactful projects across different rotations. This broad experience, combined with the skills and relationships I built, transformed my professional growth.” Francielle Mourisso First-year Fellow “Since joining Alexion, I have been inspired by its focus on rare diseases and patient support. The inclusive, collaborative culture makes me feel valued and driven. I am eager to grow through our rotations and mentorship, building a strong foundation for my career in the industry.”
Michelle Belliveau, MLS, MSRA US AD Promo Preceptor Michelle works within US Medical Affairs as an Associate Director providing Regulatory Advertising and Promotional Compliance support for marketed and investigational products within the Rare Disease Business Unit, primarily focusing on therapeutic areas within metabolics. Her prior industry experience includes Takeda Pharmaceuticals, supporting the Oncology Business Unit in various roles within Regulatory Affairs, Marketing, and Quality Assurance. Michelle attended Massachusetts College of Pharmacy and Health Sciences obtaining a Masters in Regulatory Affairs and Health Policy, as well as Simmons College, obtaining a Masters in Library and Information Science with a specialization in Archives Management. Tim O’Neill, PharmD, RPh US Medical Review Preceptor Tim is a Senior Manager serving as the US Medical Reviewer supporting the nephrology pipeline and indications. He received his PharmD from the University of Arizona in 2022 and completed a postdoctoral fellowship in Global Medical Information & Medical Affairs in affiliation with Alexion/MCPHS University. After completing the fellowship, Tim worked remotely as a consultant in Medical Information and Medical Review and served on patient advocacy panels while recovering from a stem cell transplant as treatment for a rare disease. . Marissa Lehmayer, MBA US Marketing Preceptor Marissa is an Executive Director and currently serves as the Head of Rare Hematology Marketing, covering the existing PNH business and upcoming Rare Hematology launches. In her role, she directs the development and execution of commercial strategy, oversees brand management and messaging, and advances education for healthcare providers and patient populations. Marissa is accountable for portfolio sales performance and for ensuring close alignment among cross-functional teams supporting the Rare Hematology portfolio. She holds a BA from Colgate University and an MBA from the University of North Carolina, Kenan-Flagler Business School.
Past Fellows
28
David Tao PharmD, RPh 2016-18 Associate Director Advertising and Promotion at Novartis
Calantha Yan PharmD, RPh 2020–22 Pharmacovigilance Scientist at Deciphera Pharmaceuticals
Gabriela Marcheva PharmD 2017–19 Global Medical / Clinical Research Director at Sanofi
Christine Borunda PharmD, RPh 2020–22 Senior Medical Science Liaison at Amgen
Adam Quicquaro PharmD 2018–20 Director, Clinical Development Scientist at Alexion
Michelle Ciambella PharmD, RPh 2020–22 Director, Medical Communications & Publications at Ipsen
Matthew Luen PharmD 2018–20 HCP Marketing at Amgen
Michael McDermott PharmD, RPh 2021–23 Associate Director, Safety Scientist at Bicara Therapeutics
Katie Swanner PharmD 2019–21 US Medical Director at BioMarin Pharmaceutical
Alexandra Burger PharmD 2021–23 Associate Director, US Payer Customer Marketing at Alexion
Dian Lin PharmD 2019–21 Associate Director, Value, Access & Pricing at SpringWorks Therapeutics
Janki Patel PharmD, RPh 2022-24 Associate Director, Safety Sciences and Operations at Bicara Therapeutics
Alexandra Maresh PharmD, RPh 2020–22 Associate Director, US Medical Review at Alexion
Paul Park PharmD 2022-24 Senior Manager, North America Medical at Rhythm Pharmaceuticals
30 fellows
10 years
Maya Osman PharmD 2022-24 Senior Manager, Global Medical at Amgen
Saira Jatoi PharmD 2023-25 Senior Manager, Payer Marketing at Amgen
Tim O’Neill PharmD, RPh 2022-24 Senior Manager, US Medical Review at Alexion
Rada Zunich PharmD, RPh 2023-25 Senior Manager, US Medical Communications Lead at Alexion
Tho Dao PharmD 2023-25 MSL, USMA Neurology at Alexion
Nicole Aldover PharmD, RPh 2024-26 Senior Scientific Communications Manager at Med Communications
Christina Miller PharmD, RPh 2023-25 Senior Manager, US Medical Review at Alexion
Amber Conklin PharmD, 2024-26 Manager, Regulatory Strategy at Solid Biosciences
Julia Settler PharmD, MBA 2023-25 Senior Manager, US Medical Review at Alexion
Bobby Gjorseski PharmD, RPh 2024-26 Senior Manager, Safety Scientist at Alexion
Rosetta Tolley PharmD, RPh 2023-25 Senior Manager, Safety Scientist at Alexion
Sawyer Patrick PharmD, RPh, 2024-26 US Medical Communications Lead at Alexion
Morgan Loh PharmD 2023-25 Senior Manager, US Advertising and Promotional Compliance at Alexion
Satyaharshini Reddy PharmD 2024-26 Senior Manager, Global Scientific Communications at Alexion
Aisha Khokhar PharmD, MHSc MSL at Praxis Precision Medicines
Courtney Smith PharmD, 2024-26 Senior Manager, Patient Services Strategy at Alexion
MCPHS MCPHS provides an academic environment to guide and support fellows toward a successful career in the biopharmaceutical industry. As a private institution with a history of specializing in health sciences, MCPHS offers programs that embody scholarship, professional service and community outreach. Through the affiliation with MCPHS, fellows will have the opportunity to gain teaching and research experience in an academic setting. MCPHS faculty and company program leaders
mentor fellows according to their scholarly and professional interests throughout the two-year program. As an adjunct instructor at MCPHS, fellows will have the opportunity to: Develop, coordinate and teach courses Co-precept pharmacy students on advanced experiential rotations Create and publish scholarly research and/or review articles Present research at scientific and clinical meetings Participate in professional development seminars with other MCPHS fellows
The Team Amee Mistry, PharmD, RPh Director of the Postdoctoral Biopharmaceutical Industry Fellowship Program and MCPHS faculty preceptor Dr. Mistry is a Professor of Pharmacy Practice and has been with MCPHS since 2006. She earned her PharmD at the Albany College of Pharmacy and completed a PGY1 Community Practice Residency with Walgreens and MCPHS. In 2015, Dr. Mistry took over as director of the program. She works directly with leaders in the area to continue to foster growth and development of the post graduate program and to assist the fellows in attaining positions within the pharmaceutical industry. She also continues to teach and conduct scholarly work at MCPHS, trains pharmacists and student pharmacists nationally on immunizations, and is actively involved in her state and national pharmacy organizations. Trisha LaPointe, PharmD, BCPS, FASHP, FMSHP, RPh. MCPHS faculty preceptor Dr. LaPointe is a Professor of Pharmacy Practice at MCPHS. She earned her doctorate in pharmacy from Northeastern University in 2001 and completed her PGY-1 at Massachusetts General Hospital in Boston Massachusetts. Dr. LaPointe’s current practice site at Lowell General Hospital where she sees patients in the inpatient care setting and mentors student pharmacists on inpatients general medicine rotations. Dr. LaPointe works with students, residents, and fellows to carry out scholarly pursuits.
30
Ewan McNicol, PharmD, RPh, MS MCPHS faculty preceptor Dr. McNicol is a Professor of Pharmacy Practice at MCPHS where he maintains a practice site in ambulatory pain management at Atrius Health in Boston. He received his Doctor of Pharmacy degree from MCPHS in Boston in 2016. In addition, he has a Master’s degree in Pain Research, Education and Policy from Tufts University from 2001. He conducts evidence-based reviews of analgesic interventions and outcomes for pain and related conditions, and has collaborated with current and former pharmacy fellows as a preceptor in this research.
Having exposure across a variety of teams encourages innovation and collaboration” —Aleksandar Stajic, PharmD, MBA
Sheila Seed, PharmD, MPH, CTH®, AFTM RCPS(Glasg), RPh MCPHS faculty preceptor Sheila Seed is Professor and Chair for the Department of Pharmacy Practice at the MCPHS School of Pharmacy Worcester/ Manchester campuses. During the pandemic, she served as the University’s COVID-19 Coordinator for all three campuses. She received her B.S in Pharmacy from MCPHS, Boston, Masters of Public Health from the University of Massachusetts, Amherst and Doctor of Pharmacy (Pharm.D.) from Idaho State University. She has been a faculty member at MCPHS since 2001. Prior to her appointment, she worked in the community setting and as a pharmacy officer in the U.S. Air Force. She has a Certificate of Travel Health™ (CTH)®, and is an Associate Faculty Member of Travel Medicine at the Royal College of Physicians and Surgeons (Glasgow). She has served as the Secretary of Knowledge Management and the Chair of the AACP Public Health SIG and a past Coordinator of the APhA Immunization SIG. She continues to work with the SIG on updating the APhA Travel Health Quick Guide annually. Yulia Murray, PharmD, RPh MCPHS Faculty Preceptor Dr. Murray received her Doctor of Pharmacy degree from MCPHS University in Worcester, and completed her Pharmacy Practice Residency at Beth Israel Deaconess Medical Center in Boston. Following her residency, she practiced as a Clinical Medicine Pharmacist at Boston Medical Center before transitioning to a
full-time faculty role at MCPHS University. She is currently an Associate Professor of Pharmacy Practice at the MCPHS University School of Pharmacy–Boston. Her clinical practice is at Newton-Wellesley Hospital, where she serves as a clinical pharmacist on the adult internal medicine service and precepts students on both IPPE and APPE rotations. Dr. Murray serves as Chair of the Interprofessional Education (IPE) Committee for the School of Pharmacy–Boston. She is actively involved in several professional pharmacy organizations and currently serves as a Director for the Massachusetts Society of Health-System Pharmacists. Phung C. On, PharmD, BCPS, RPh MCPHS Faculty Preceptor Dr. Phung On is an Associate Professor of Pharmacy Practice at MCPHS. She is the Academic Coordinator on the Boston Campus for the fellowship program and the Community Engagement Coordinator for the School of Pharmacy – Boston. She earned her Doctor of Pharmacy degree from MCPHS and completed a PGY1 Pharmacy Practice Residency with a focus on ambulatory care, managed care, and transitions of care at the University of North Carolina at Chapel Hill and AccessCare, a network of the Community Care of North Carolina. Dr. On maintains a clinical practice site in ambulatory care at Codman Square Health Center in Boston where she works collaboratively with the primary care team to manage patients’ chronic diseases.
Application Requirements Eligibility The MCPHS Biopharmaceutical Industry fellows will be selected on a nationally competitive basis. Applicants must have a Doctor of Pharmacy degree from an ACPE accredited college of pharmacy at the commencement of the program. • Candidates must have strong written and verbal communication skills and a strong interest in pursuing a career within the biopharmaceutical industry.
place in December during ASHP. Candidates will be notified if selected for an interview. The process is rigorous and competitive; therefore, candidates should submit their applications well in advance of posted deadlines as priority will be given to those who apply early.
ASHP Midyear & Onsite Interviews
• All candidates must have authorization to work in the United States throughout the duration of the one or two year fellowship. No visa sponsorship will be provided (i.e., TN, H-1B, STEM OPT, etc.).
The fellowship program will be conducting in-person interviews at the ASHP Midyear Clinical Meeting in Orlando, FL. Attendance is strongly encouraged, but not required. Candidates attending in-person will not be able to interview without registering for both ASHP and PPS. Please refer to the ASHP & PPS website for registration details.
Application Procedure
Top candidates may be invited for interviews at the sponsoring company’s location.
The MCPHS application portal (SMApply) will open on Monday October 5, 2026. Applicants must upload the following application materials to the online portal (mcphs.smapply.io) by Monday November 2, 2026: • Letter of intent (addressed to the company specific program director/lead; found in each company brochure) • Curriculum vitae • Unofficial college transcript • Contact information for three references. References will receive an electronic recommendation form to complete separately. • Three recommendation evaluation forms must be submitted no later than Friday November 20, 2026 via the online portal. This is NOT a letter of recommendation but an online form that the recommender will receive for completion from SMApply.
Application Review & Interview Timeline Following a review of submitted applications, prescreens and preliminary interviews will begin in October. Additional interviews, including final rounds will take
AIFA First Offer Date The choice of a Postdoctoral Fellowship is an important decision. MCPHS, in conjunction with the Alliance of Industry Fellowship Associates (AIFA), has aligned to extend offers for Fellowships no earlier than Friday December 11, 2026. We believe this is a positive reflection of the cultures our Programs offer and that culture is a critical consideration in choice of Fellowship. We hope that other academic and non-academic Fellowship Programs will NOT pressure candidates to accept offers prior to this aligned offer date.
Onboarding Final candidates will be required to go through additional screening / onboarding as required by MCPHS. For more information, please email: PharmD.Fellowships@alexion.com
Manchester Campus 1260 Elm Street, Manchester, NH 03101 Boston Campus 179 Longwood Avenue, Boston, MA 02115-5896
Worcester Campus 19 Foster Street, Worcester, MA 01608-1715
Alexion Pharmaceuticals, Inc. 121 Seaport Boulevard, Boston, MA 02210
32